JP2019194236A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194236A5
JP2019194236A5 JP2019127476A JP2019127476A JP2019194236A5 JP 2019194236 A5 JP2019194236 A5 JP 2019194236A5 JP 2019127476 A JP2019127476 A JP 2019127476A JP 2019127476 A JP2019127476 A JP 2019127476A JP 2019194236 A5 JP2019194236 A5 JP 2019194236A5
Authority
JP
Japan
Prior art keywords
compound
salt
compound according
group
compound selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019127476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019194236A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019194236A publication Critical patent/JP2019194236A/ja
Publication of JP2019194236A5 publication Critical patent/JP2019194236A5/ja
Priority to JP2022041396A priority Critical patent/JP7375072B2/ja
Pending legal-status Critical Current

Links

JP2019127476A 2014-09-17 2019-07-09 Mk2阻害剤およびその使用 Pending JP2019194236A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022041396A JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017515845A Division JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022041396A Division JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Publications (2)

Publication Number Publication Date
JP2019194236A JP2019194236A (ja) 2019-11-07
JP2019194236A5 true JP2019194236A5 (https=) 2019-12-19

Family

ID=55454109

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515845A Active JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用
JP2019127476A Pending JP2019194236A (ja) 2014-09-17 2019-07-09 Mk2阻害剤およびその使用
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017515845A Active JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Country Status (30)

Country Link
US (5) US9458175B2 (https=)
EP (2) EP3912981A1 (https=)
JP (3) JP6556225B2 (https=)
KR (1) KR102457848B1 (https=)
CN (1) CN106998692B (https=)
AU (1) AU2015317741B2 (https=)
BR (1) BR112017005266B1 (https=)
CA (1) CA2961607C (https=)
CL (1) CL2017000576A1 (https=)
CO (1) CO2017003279A2 (https=)
CY (1) CY1124215T1 (https=)
DK (1) DK3193611T3 (https=)
EA (1) EA037299B1 (https=)
EC (1) ECSP17023281A (https=)
ES (1) ES2874561T3 (https=)
HR (1) HRP20210529T1 (https=)
HU (1) HUE054347T2 (https=)
IL (1) IL251051B (https=)
LT (1) LT3193611T (https=)
MA (1) MA40534B1 (https=)
MX (2) MX373341B (https=)
PL (1) PL3193611T3 (https=)
PT (1) PT3193611T (https=)
RS (1) RS62017B1 (https=)
SA (1) SA517381115B1 (https=)
SG (2) SG11201701861RA (https=)
SI (1) SI3193611T1 (https=)
SM (1) SMT202100311T1 (https=)
TW (1) TWI744217B (https=)
WO (1) WO2016044463A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
EP3596085A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
WO2020072580A1 (en) * 2018-10-02 2020-04-09 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20220154094A (ko) * 2020-02-14 2022-11-21 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 억제제를 이용한 단일 및 병용 요법
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
JP2023550347A (ja) * 2020-11-12 2023-12-01 アクティーヴァ セラピューティクス, インコーポレイテッド 血管漏出障害および内皮バリア障害を処置することにおける使用のためのmk2活性化化合物
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
EP4608401A2 (en) * 2022-10-27 2025-09-03 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof
JP2026505836A (ja) * 2023-02-07 2026-02-18 セルジーン コーポレーション Mk2キナーゼ分解剤として有用である化合物および組成物
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP4734346B2 (ja) 2005-02-04 2011-07-27 セノミックス インコーポレイテッド 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
WO2014011902A1 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EA201590644A1 (ru) * 2012-09-24 2015-09-30 Клермонт Спиде Способ и система с управляемыми мобильным отправителем доступом к данным и удалением данных
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Gsk3抑制劑與抗dr5抗體之組合
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법

Similar Documents

Publication Publication Date Title
JP2019194236A5 (https=)
JP2018024670A5 (https=)
JP2020515557A5 (https=)
JP2022078315A5 (https=)
JP2021020948A5 (https=)
JP2017008120A5 (https=)
JP2018030858A5 (https=)
JP2018168171A5 (https=)
JP2018521020A5 (https=)
JP2019207442A5 (https=)
JP2009149903A5 (https=)
JP2013532130A5 (https=)
JP2017186358A5 (https=)
JP2018150298A5 (https=)
JP2017222697A5 (https=)
JP2018536572A5 (https=)
JP2011518833A5 (https=)
JP2009535462A5 (https=)
JP2010501534A5 (https=)
JP2011527560A5 (https=)
JP2019048806A5 (https=)
JP2012111758A5 (https=)
JP2016153424A5 (https=)
JP2012107057A5 (https=)
JP2016520672A5 (https=)